Anastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, Warren L Wu, Eric Bartnicki, Triantafyllia Karakousi, Sahith Rajalingam, Alberto Herrera, Angeliki Karatza, Ali Rashidfarrokhi, Sabrina Solis, Metamia Ciampricotti, Anna H Yeaton, Ellie Ivanova, Corrin A Wohlhieter, Terkild B Buus, Makiko Hayashi, Burcu Karadal-Ferrena, Harvey I Pass, John T Poirier, Charles M Rudin, Kwok-Kin Wong, Andre L Moreira, Kamal M Khanna, Aristotelis Tsirigos, Thales Papagiannakopoulos, Sergei B Koralov
Lung cancer treatment has benefited greatly through advancements in immunotherapies. However, immunotherapy often fails in patients with specific mutations like KEAP1, which are frequently found in lung adenocarcinoma. We established an antigenic lung cancer model and used it to explore how Keap1 mutations remodel the tumor immune microenvironment. Using single-cell technology and depletion studies, we demonstrate that Keap1-mutant tumors diminish dendritic cell and T cell responses driving immunotherapy resistance...
October 25, 2023: Cell Reports